VANCOUVER, BC, Aug. 8, 2022 /PRNewswire/ -- Ondine Biomedical Inc. (LON:OBI.LN), has recruited the final patient to its nasal photodisinfection exploratory Phase 2 trial. The trial is evaluating how effectively Ondine's nasal photodisinfection technology eradicates pathogens – specifically Staphylococcus aureus - in the nose.
Read more at prnewswire.comOndine Biomedical completes patient recruitment for US Phase II nasal photodisinfection trial
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here